This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Daiichi Sankyo Co., Ltd.
Drug Names(s): U3 1565
Description: U3-1565 is a fully human monoclonal antibody directed against human heparin-binding epidermal growth factor-like growth factor (HB-EGF) a member of the EGF family of ligands that bind to and activate the EGFR and HER4. HB-EGF-mediated activation of its target receptors results in oncogenic signaling.
In June 2002, U3 Pharma and Abgenix announced the formation of a collaboration to discover, develop and potentially commercialize fully human monoclonal antibody therapies directed against, validated proprietary drug targets selected from U3 Pharma's portfolio, including U3-1287. Both parties will conduct in vitro and in vivo studies of the antibody candidates. Subsequently, Abgenix and U3 Pharma will have the right to co-develop and commercialize antibody products discovered during the collaboration. The parties will share equally in the development costs and any potential profits from sales of any co-developed products.
In April 2006, Amgen completed its acquisition of Abgenix.
In May 2008, Daiichi Sankyo announced that it entered into an agreement to acquire U3 Pharma.
Partners: Amgen, Inc.
Additional information available to subscribers only: